Table 2 Associations of PODXL expression with clinicopathological factors in the pooled cohort
PODXL negative n (%) | PODXL positive n (%) | p | |
|---|---|---|---|
N | 55 | 170 | |
Age (years) | |||
Mean | 69.5 | 67.3 | 0.250 |
Median | 68.5 | 67.7 | |
Range | 42.6–88.8 | 21.1–94.4 | |
Sex | |||
Female | 20 (36.4) | 43 (25.3) | 0.122 |
Male | 35 (63.6) | 127 (74.7) | |
Location | |||
Esophagus | 23 (41.8) | 102 (60.0) | 0.020 |
Stomach | 32 (58.2) | 68 (40.0) | |
cT stage | |||
T1 | 1 (1.8) | 7 (4.1) | 0.413 |
T2 | 31 (56.4) | 75 (44.1) | |
T3 | 22 (40.0) | 85 (50.0) | |
T4 | 1 (1.8) | 3 (1.8) | |
cN stage | |||
N0 | 39 (70.9) | 110 (64.7) | 0.422 |
N1 | 12 (21.8) | 43 (25.3) | |
N2 | 3 (5.5) | 14 (8.2) | |
N3 | 1 (1.8) | 3 (1.8) | |
cM stage | |||
M0 | 51 (92.7) | 161 (94.7) | 0.525 |
M1 | 4 (7.3) | 9 (5.3) | |
Differentiation | |||
Low grade | 3 (5.5) | 6 (3.6) | 0.241 |
Intermediate grade | 23 (41.8) | 59 (35.1) | |
High grade | 29 (52.7) | 103 (61.3) | |
Missing data | 2 | ||
Lauren classification | |||
Intestinal | 42 (76.4) | 109 (64.5) | 0.274 |
Mixed | 0 | 15 (8.9) | |
Diffuse | 13 (23.6) | 45 (26.6) | |
Missing data | 1 | ||
Residual tumor status | |||
R0 | 45 (81.8) | 128 (75.3) | 0.392 |
R1 | 8 (14.5) | 35 (20.6) | |
R2 | 2 (3.6) | 7 (4.1) | |
Number of examined nodes | |||
Mean | 30 | 34 | 0.149 |
Median | 28 | 32 | |
Range | 5–85 | 1–112 | |
Treatment | |||
Surgery only | 30 (54.5) | 119 (70.0) | 0.048 |
Neoadjuvant chemotherapya | 25 (45.5) | 51 (30.0) | |
Follow-up (years from resection) | |||
Median (95% CI) | 7.2 (6.6–7.7) | 7.3 (6.7–7.6) | 0.125 |